Collectively, increased expression of DILA1, Cyclin D1, and p-Rb(Ser780) protein are associated with tamoxifen resistance and poor prognosis of ER-positive breast cancer patients who received adjuvant tamoxifen treatment, consistent with the findings in tamoxifen-resistant breast cancer cell lines. The gene discussed is RB1; the disease is breast carcinoma.